NPJ Vaccines最新文献

Global vaccine confidence trends among adults above and below age 65. 65岁以上及以下成年人的全球疫苗信心趋势。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-21 DOI: 10.1038/s41541-025-01217-7

Bei Liu, Xiyu Zhang, Yongqiang Lai, Tao Sun, Chao Wang, Tianshuo Zhao, Sihui Zhang, Baoguo Shi, Ye Li, Fuqiang Cui

{"title":"Global vaccine confidence trends among adults above and below age 65.","authors":"Bei Liu, Xiyu Zhang, Yongqiang Lai, Tao Sun, Chao Wang, Tianshuo Zhao, Sihui Zhang, Baoguo Shi, Ye Li, Fuqiang Cui","doi":"10.1038/s41541-025-01217-7","DOIUrl":"https://doi.org/10.1038/s41541-025-01217-7","url":null,"abstract":"This study is interested in global vaccine confidence because it directly impacts vaccination rates and public health outcomes, especially during the COVID-19 pandemic. Furthermore, due to the unique vulnerabilities to vaccine-preventable diseases, misinformation, and access to health information among adults aged 65 and older, understanding vaccine confidence in this population is crucial for developing targeted interventions and improving vaccination rates. The current research is limited by single-country surveys and cross-sectional designs, providing limited insights into these issues. We compared the vaccine confidence between the population over 65 and under 65 in terms of vaccine safety, effectiveness, compatibility with religious beliefs, and importance to children. We employed a hierarchical logistic model, and compared human development index (HDI) values to investigate determinants of vaccine confidence. Vaccine confidence increased between 2015 and 2019, but decreased between 2019 and 2022 across most global regions, exhibiting an inverted U-shaped trend. Population over 65 in high-income countries was more likely to agree on the safety, effectiveness, importance to children, and compatibility of vaccines with religious beliefs than those under 65, with agreement levels exceeding 80% for most aspects. Gender, education, income, and religion influenced vaccine attitudes among adults aged 65 and older. Countries with an HDI exceeding 0.9 consistently demonstrated positive trends in vaccine confidence. This relationship between HDI and vaccine confidence underscores the importance of comprehensive societal development in shaping attitudes toward vaccination. These findings can help develop targeted interventions and policies to improve vaccination rates among older adults.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"160"},"PeriodicalIF":6.9,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine. 溶瘤病毒介导的p53激活增强了p53转导树突状细胞疫苗的抗肿瘤免疫。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-19 DOI: 10.1038/s41541-025-01219-5

Motohiko Yamada, Hiroshi Tazawa, Kanto Suemori, Naohiro Okada, Yoshinori Kajiwara, Ryohei Shoji, Yasuo Nagai, Hiroaki Inoue, Naoyuki Hashimoto, Nobuhiko Kanaya, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Michiue, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

{"title":"Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine.","authors":"Motohiko Yamada, Hiroshi Tazawa, Kanto Suemori, Naohiro Okada, Yoshinori Kajiwara, Ryohei Shoji, Yasuo Nagai, Hiroaki Inoue, Naoyuki Hashimoto, Nobuhiko Kanaya, Satoru Kikuchi, Shinji Kuroda, Hiroyuki Michiue, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"10.1038/s41541-025-01219-5","DOIUrl":"10.1038/s41541-025-01219-5","url":null,"abstract":"Dendritic cells (DCs) transduced with replication-deficient, wild-type human p53-expressing adenovirus Ad-p53 (Ad-p53 DCs) induce p53-targeting cytotoxic T lymphocytes (CTLs). However, the antitumor efficacy of Ad-p53 DCs is diminished by weak p53 immunogenicity in tumor cells and poor immune responses. We developed a p53-armed oncolytic adenovirus, OBP-702, to induce tumor-specific p53 expression and antitumor immune response, suggesting a role for OBP-702 in enhancing the antitumor efficacy of Ad-p53 DCs. The combined effect of Ad-p53 DCs and OBP-702 was investigated using murine colon cancer (CC) tumor models. Ad-p53 DCs were obtained by stimulating bone marrow-derived cells with granulocyte-macrophage colony-stimulating factor, interleukin-4, and Ad-p53. Subcutaneous tumor models of CT26 (p53 wild-type) and MC38 (p53 mutant-type) murine CC cell lines were used to evaluate the therapeutic potential of combination therapy in the terms of tumor growth, abscopal effect, antitumor immune response, and presentation of p53 peptides in tumor cells. Combination therapy with Ad-p53 DCs and OBP-702 significantly suppressed the growth of p53-intact CT26 tumors at treated and untreated sites by inducing tumor-infiltration of CD8+ CTLs and CD11c+ DCs. OBP-702-infected tumor cells presented human p53 epitopes in the context of major histocompatibility complex molecules, which were recognized by CTLs induced by Ad-p53 DCs. Combination therapy significantly suppressed the growth of p53-mutant MC38 tumors by activating the antitumor immune response. Our results suggest that OBP-702-mediated presentation of p53 epitopes on tumor cells enhances the antitumor efficacy of Ad-p53 DCs against murine CC tumors by attracting p53-targeting CTLs.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"158"},"PeriodicalIF":6.9,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants. 基于多种抗原的SARS-CoV-2疫苗可提供更高的免疫应答和对SARS-CoV-2变体的保护。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-19 DOI: 10.1038/s41541-025-01198-7

Marwa Alhashimi, Ekramy E Sayedahmed, Ahmed Elkashif, Shubhada K Chothe, Wen-Chien Wang, Muralimanohara S T Murala, Vivek Gairola, Nobuko Wakamatsu, Abhinay Gontu, Santhamani Ramasamy, Lindsey LaBella, Padmaja Jakka, Meera Surendran Nair, Ruth H Nissly, Suresh V Kuchipudi, Suresh K Mittal

{"title":"A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants.","authors":"Marwa Alhashimi, Ekramy E Sayedahmed, Ahmed Elkashif, Shubhada K Chothe, Wen-Chien Wang, Muralimanohara S T Murala, Vivek Gairola, Nobuko Wakamatsu, Abhinay Gontu, Santhamani Ramasamy, Lindsey LaBella, Padmaja Jakka, Meera Surendran Nair, Ruth H Nissly, Suresh V Kuchipudi, Suresh K Mittal","doi":"10.1038/s41541-025-01198-7","DOIUrl":"10.1038/s41541-025-01198-7","url":null,"abstract":"The emergence of divergent SARS-CoV-2 variants has significantly compromised the effectiveness of first-generation COVID-19 vaccines. We investigated a prime-boost approach using bovine adenoviral (Ad) [BAd] and human Ad (HAd) vectors expressing the spike (S), membrane (M), or nucleocapsid (N) with the autophagy-inducing peptide C5 (AIP-C5) for enhanced antigen-specific immunity. The combinational vaccine formulation expressing three antigens demonstrated markedly elevated antigen-specific cell-mediated immune (CMI) responses compared to groups immunized with vectors expressing individual antigens. Furthermore, vaccinated animals exhibited 100% survival, significant reductions in lung viral titers, and no apparent signs of morbidity following challenges with Delta or Omicron variants in K18-hACE2 transgenic mice. Surprisingly, immunization with vectors expressing M and N resulted in immune suppression. However, including S with M and N overcomes this antagonistic interaction and significantly enhances immune responses and protection efficacy. Using the BAd vaccine platform in a multi-antigen approach complemented with AIP-C5 is a promising strategy for developing next-generation SARS-CoV-2 vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"159"},"PeriodicalIF":6.9,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing human B cell repertoire analyses to interpret clinical data and design sequential HIV vaccines. 优化人类B细胞库分析，以解释临床数据和设计顺序HIV疫苗。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-17 DOI: 10.1038/s41541-025-01168-z

Milton Maciel, Lindsey R Baden, Brian Briney, Nicole A Doria-Rose, Kasalina N Kiwanuka, Shelly J Krebs, Angela Malaspina, Georgia D Tomaras, Andrew Ward, Gunilla B Karlsson Hedestam, Wilton B Williams, M Patricia D'Souza

引用次数: 0

Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia. 澳大利亚mRNA - COVID-19疫苗接种后心肌炎监测及随访结果

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-16 DOI: 10.1038/s41541-025-01206-w

Lucy Deng, Amanda Van Eldik, Megan O'Moore, Jim Buttery, Abigail Cheung, Nicholas Cox, Carla Drake-Brockman, Nathan Dwyer, Paul Effler, Michael Gold, Pravin Hissaria, Andrew Kelly, Sarah Khanlari, Claire Larter, Shannon Melody, Michael Nissen, Rajesh Puranik, James Rankin, Sally Singleton, Liza Thomas, Sudhir Wahi, Gavin Wheaton, Dominica Zentner, Kristine Macartney, Clara K Chow, Nicholas Wood

{"title":"Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia.","authors":"Lucy Deng, Amanda Van Eldik, Megan O'Moore, Jim Buttery, Abigail Cheung, Nicholas Cox, Carla Drake-Brockman, Nathan Dwyer, Paul Effler, Michael Gold, Pravin Hissaria, Andrew Kelly, Sarah Khanlari, Claire Larter, Shannon Melody, Michael Nissen, Rajesh Puranik, James Rankin, Sally Singleton, Liza Thomas, Sudhir Wahi, Gavin Wheaton, Dominica Zentner, Kristine Macartney, Clara K Chow, Nicholas Wood","doi":"10.1038/s41541-025-01206-w","DOIUrl":"10.1038/s41541-025-01206-w","url":null,"abstract":"Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccinations remains an important but undefined public health concern. We conducted prospective follow-up of individuals with either confirmed or probable myocarditis following monovalent Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccination between 21 April 2021 and 5 July 2022 in Australia. Of 256 individuals who consented to follow up, mostly males following a second dose, 60% (133/221) had ongoing symptoms at 3-6 months and 35% (81/231) at 12-18 months. Self-reported ongoing exercise restrictions, medication requirements, and hospital re-presentations were associated with ongoing symptoms, as was a lower self-reported health status and quality of life. Clinical severity remained mild, with low hospitalisation rates and no deaths in the follow-up period and health-related quality of life improved over time. These findings support ongoing use of mRNA COVID-19 vaccines in at-risk individuals to prevent disease caused by SARS-CoV-2 infection.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"155"},"PeriodicalIF":6.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine. TLR7/8激动剂ni -4001增强了波瓦桑病毒样颗粒疫苗的免疫原性。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-16 DOI: 10.1038/s41541-025-01215-9

Michael W Crawford, Walid M Abdelwahab, Karthik Siram, Christopher J Parkins, Henry F Harrison, E Taylor Stone, Samantha R Osman, Dillon Schweitzer, David J Burkhart, Amelia K Pinto, James D Brien, Jessica L Smith, Alec J Hirsch

{"title":"The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.","authors":"Michael W Crawford, Walid M Abdelwahab, Karthik Siram, Christopher J Parkins, Henry F Harrison, E Taylor Stone, Samantha R Osman, Dillon Schweitzer, David J Burkhart, Amelia K Pinto, James D Brien, Jessica L Smith, Alec J Hirsch","doi":"10.1038/s41541-025-01215-9","DOIUrl":"10.1038/s41541-025-01215-9","url":null,"abstract":"Powassan virus (POWV) is a pathogenic tick-borne flavivirus that causes fatal neuroinvasive disease in humans. There are currently no approved therapies or vaccines for POWV infection. Here, we develop a POW virus-like particle (POW-VLP) based vaccine adjuvanted with the novel synthetic Toll-like receptor 7/8 agonist INI-4001. We demonstrate that INI-4001 outperforms both alum and the Toll-like receptor 4 agonist INI-2002 in enhancing the immunogenicity of a dose-sparing POW-VLP vaccine in mice. INI-4001 increases the magnitude and breadth of the antibody response as measured by whole-virus ELISA, induces neutralizing antibodies measured by FRNT, reduces viral burden in the brain of infected mice measured by RT-qPCR, and confers 100% protection from lethal challenge with both lineages of POWV. We show that the antibody response induced by INI-4001 is more durable than standard alum, and 80% of mice remain protected from lethal challenge 9-months post-vaccination. Lastly, we show that the protection elicited by INI-4001 adjuvanted POW-VLP vaccine is unaffected by either CD4+ or CD8+ T cell depletion and can be passively transferred to unvaccinated mice indicating that protection is mediated through humoral immunity. This study highlights the utility of novel synthetic adjuvants in VLP-based vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"156"},"PeriodicalIF":6.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-12 mRNA-LNP promotes dermal resident memory CD4⁺ T cell development. IL-12 mRNA-LNP促进皮肤常驻记忆CD4+ T细胞发育。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-16 DOI: 10.1038/s41541-025-01213-x

Anabel Zabala-Peñafiel, Claudia Gonzalez-Lombana, Mohamad-Gabriel Alameh, Lais A Sacramento, Zhirong Mou, Anthony T Phan, Emily A Aunins, Ying K Tam, Jude E Uzonna, Drew Weissman, Christopher A Hunter, Phillip Scott

{"title":"IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development.","authors":"Anabel Zabala-Peñafiel, Claudia Gonzalez-Lombana, Mohamad-Gabriel Alameh, Lais A Sacramento, Zhirong Mou, Anthony T Phan, Emily A Aunins, Ying K Tam, Jude E Uzonna, Drew Weissman, Christopher A Hunter, Phillip Scott","doi":"10.1038/s41541-025-01213-x","DOIUrl":"10.1038/s41541-025-01213-x","url":null,"abstract":"Dermal resident memory CD4+ T cells (dTrm) provide protection against vector-borne infections. However, the factors that promote their development remain unclear. We tested if an mRNA vaccine, encoding a protective leishmanial antigen, induced dTrm cells. The mRNA vaccine induced robust systemic T-cell responses, but few Trm cells were found in the skin. Since IL-12 promotes Th1 responses, we tested whether IL-12 mRNA combined with the mRNA vaccine could enhance dTrm cell development. This combination significantly expanded Leishmania-specific Th1 cells expressing skin-homing molecules and memory T cell markers in the draining lymph node. Additionally, higher numbers of dTrm cells were maintained in the skin, and mice exhibited functional immunity indicated by a delayed hypersensitivity response and protection upon challenge with Leishmania. These findings highlight IL-12 as a key driver of CD4+ dTrm development, enabling their global seeding across the skin, and underscore the potential of IL-12-enhanced mRNA vaccines to generate durable immunity against cutaneous leishmaniasis and other skin-targeted infections.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"154"},"PeriodicalIF":6.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines. 先前的人类地方性冠状病毒暴露不影响对SARS-CoV-2蛋白疫苗的体液反应。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-13 DOI: 10.1038/s41541-025-01203-z

Guy de Bruyn, Haritha Adhikarla, Caroline K Brackett, Yichen Jia, Premkumar Lakshmanane, Sarah V Mudrak, Sheetal Sawant, Donghui Zhang, Roman M Chicz, Saranya Sridhar, Georgia D Tomaras, Kelly E Seaton

引用次数: 0

A live attenuated NS1-deficient vaccine candidate for cattle-origin influenza A (H5N1) clade 2.3.4.4.b viruses. 牛源甲型H5N1进化枝2.3.4.4减毒ns1缺陷活疫苗候选株。乙型流感病毒。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-12 DOI: 10.1038/s41541-025-01207-9

Ahmed Mostafa, Chengjin Ye, Ramya S Barre, Vinay Shivanna, Reagan Meredith, Roy N Platt, Ruby A Escobedo, Mahmoud Bayoumi, Esteban M Castro, Nathaniel Jackson, Anastasija Cupic, Aitor Nogales, Timothy J C Anderson, Adolfo García-Sastre, Luis Martinez-Sobrido

{"title":"A live attenuated NS1-deficient vaccine candidate for cattle-origin influenza A (H5N1) clade 2.3.4.4.b viruses.","authors":"Ahmed Mostafa, Chengjin Ye, Ramya S Barre, Vinay Shivanna, Reagan Meredith, Roy N Platt, Ruby A Escobedo, Mahmoud Bayoumi, Esteban M Castro, Nathaniel Jackson, Anastasija Cupic, Aitor Nogales, Timothy J C Anderson, Adolfo García-Sastre, Luis Martinez-Sobrido","doi":"10.1038/s41541-025-01207-9","DOIUrl":"10.1038/s41541-025-01207-9","url":null,"abstract":"Avian Influenza viruses (AIVs) present a public health risk, especially with seasonal vaccines offering limited protection. AIV H5N1 clade 2.3.4.4b has caused a multi-state outbreaks in the United States (US) poultry and cattle since March 2024, raising pandemic concerns. We developed a nonstructural protein 1 (NS1)-deficient mutant of a low pathogenic version of the cattle-origin human influenza A/Texas/37/2024 H5N1, namely LPhTXdNS1, and assessed its safety, immunogenicity, and protection efficacy. LPhTXdNS1 is attenuated in vitro, showing reduced replication efficiency in Vero cells and inability to control IFNβ promoter activation. The LPhTXdNS1-immunized C57BL/6 J mice exhibit significantly reduced viral replication and pathogenicity compared to those infected with the low pathogenic version expressing NS1, namely LPhTX. Notably, a single intranasal dose of LPhTXdNS1 elicited protective immune responses, providing robust protection against lethal wild-type H5N1 challenge. These results demonstrate that LPhTXdNS1 is safe and able to induce protective immune responses against H5N1.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"151"},"PeriodicalIF":6.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles. 利用PreF形成包膜病毒样颗粒改良的基于mrna的RSV疫苗。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2025-07-12 DOI: 10.1038/s41541-025-01205-x

Pengdi Chai, Yi Shi, Xiaoyan Li, Mengyao Yang, Xiafei Liu, Mei Liu, Junjie Yu, Xiaoxuan Yin, Dongwei Li, Ke Li, Xiangyu Kong, Qin Zhang, Hong Wang, Xiaoman Sun, Jinsong Li, Lili Li, Dandi Li, Lili Pang, Xuancheng Lu, Zhaojun Duan

{"title":"Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles.","authors":"Pengdi Chai, Yi Shi, Xiaoyan Li, Mengyao Yang, Xiafei Liu, Mei Liu, Junjie Yu, Xiaoxuan Yin, Dongwei Li, Ke Li, Xiangyu Kong, Qin Zhang, Hong Wang, Xiaoman Sun, Jinsong Li, Lili Li, Dandi Li, Lili Pang, Xuancheng Lu, Zhaojun Duan","doi":"10.1038/s41541-025-01205-x","DOIUrl":"10.1038/s41541-025-01205-x","url":null,"abstract":"Respiratory syncytial virus (RSV) causes severe respiratory disease in infants and the elderly. However, natural infection fails to induce durable immune protection, and existing mRNA vaccines for older adults exhibit limited long-term efficacy. We developed an antigen engineering strategy inserting ESCRT/ALIX-binding region (EABR) into truncated RSV prefusion F (PreF) cytoplasmic tails to form enveloped virus-like particles (eVLPs). In murine models, PreF-EABR mRNA vaccines elicited higher, more persistent neutralizing antibodies than conventional PreF mRNA, correlating with enhanced germinal center B cell and memory B cell responses. A lower dose of PreF-EABR mRNA (1 μg) suppressed viral load and pathology comparable to higher-dose PreF mRNA (2.5 μg). Transcriptomic analysis showed PreF-EABR mRNA activated toll-like receptor and chemokine signaling pathways, enhancing antibody longevity via platelet-associated signatures. This study explores the development and possible mechanism of long-lasting RSV mRNA vaccines by eVLPs technology, which also suggest its potential application in other vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"152"},"PeriodicalIF":6.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144619447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0